相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
Nathan I. Cherny et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Zi-Xian Wang et al.
JAMA NETWORK OPEN (2019)
Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point
Bo Huang et al.
PHARMACEUTICAL STATISTICS (2018)
Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care
Omer Ben-Aharon et al.
JAMA ONCOLOGY (2018)
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?
Lowell E. Schnipper et al.
JAMA ONCOLOGY (2018)
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework
Nathan I. Cherny et al.
JAMA ONCOLOGY (2018)
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework
Alexandre Vivot et al.
JAMA ONCOLOGY (2018)
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework Reply
Omer Ben-Aharon et al.
JAMA ONCOLOGY (2018)
Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Sierra Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials A Meta-analysis
Gideon M. Blumenthal et al.
JAMA ONCOLOGY (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
Ludovic Trinquart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Medians and Milestones in Describing the Path to Cancer Cures Telling Tails
Matthew D. Hellmann et al.
JAMA ONCOLOGY (2016)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
分享论文
